Access Pharma Gains SFDA Approval for Oral Mucositis Treatment

Access Pharmaceuticals announced that MuGard™, its treatment for oral mucositis in cancer patients, received SFDA marketing approval. RHEI Pharmaceuticals HK Ltd. handled the regulatory process for Access, and Jian An Pharma will market the product in China and Taiwan. Access out-licensed China rights for MuGard to RHEI Pharma in 2008. More details.... Stock Symbol: (OTCBB: ACCP) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});